Articles by Haralambos Kalofonos, MD
95 monarchE: Subgroup Analysis of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer by Nodal Status
ByJavier Cortés, MD,Stephen R.D. Johnston,Miguel Martin, MD, PhD,Sara M. Tolaney, MD, MPH,Matthew P. Goetz, MD,Hope S. Rugo, MD,Joohyuk Sohn,Ozgur Ozyilkan,Miguel Henriques Abreu,Matthias Zaiss,Karina Maia Vianna,Hanne Melgaard Nielsen,Arlene Chan,Haralambos Kalofonos, MD,Serafin Morales,Belen San Antonio,Maria Munoz Fernandez,Sasha Amdur,Patrick Neven, MD, PhD,Brenda Grimes 
Paclitaxel and Carboplatin as First-Line Chemotherapy for Advanced Breast Cancer
ByGeorge Fountzilas, MD,Dimitrios Bafaloukos, MD,Gerasimos Aravantinos, MD,Constantine Nicolaides, MD,Haralambos Kalofonos, MD,Pavlos Papakostas, MD,Nicholaos Xiros, MD,Evalgelia Razi, MD In a phase II study, 66 patients with advanced breast cancer (median age 56 years; range, 28 to 75 years) were treated with paclitaxel (Taxol), 175 mg/m² infused over 3 hours, and carboplatin (Paraplatin), dosed to attain an